A volunteer receives the first dose of a rapidly developed Ebola vaccine in a UK trial run by Oxford University, targeting the Bundibugyo strain. The vaccination takes place as researchers and health organisations work to address an ongoing outbreak in the Democratic Republic of Congo (DRC) and Uganda that began in May. Multiple reports cite deaths linked to the outbreak exceeding 1,000, with one source placing the total at over 1,270. The World Health Organization is referenced as estimating more than 1,000 deaths across the two countries since the outbreak emerged. The vaccine is presented as specifically aimed at the Bundibugyo strain, which is described as relatively rare but is responsible for a large, deadly outbreak. The reports indicate this first dose marks the beginning of clinical evaluation in the trial and is part of wider efforts to develop vaccine and treatment options for the crisis. Additional details on dosing, trial phase, and participant follow-up are not included in the excerpts.